TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
Want to see HK:1875 full AI Analyst Report?
1875 Stock Chart & Stats
HK$2.50
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.50
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.70 - HK$5.87
Previous CloseN/A
Volume400.00
Average Volume (3M)240.51K
Market Cap
HK$3.38B
Enterprise ValueHK$2.81B
Total Cash (Recent Filing)HK$328.47M
Total Debt (Recent Filing)HK$383.72M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding772,787,900
10 Day Avg. Volume141,880
30 Day Avg. Volume240,506
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.60
Price to Sales (P/S)2.18
P/FCF Ratio-60.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$1.61B
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsThe business earns revenue from product sales and from contract development & GMP manufacturing services, plus potential licensing. This durable mix reduces reliance on a single commercial product, creates multiple revenue levers, and can stabilize cash receipts across product cycles.
GMP Manufacturing & Complex Injectable ExpertiseIn-house GMP capabilities and specialization in specialty/complex injectables create structural advantages: regulatory-compliant scale, higher technical barriers to entry, and attractiveness to outsourcing pharma clients. These capabilities support sustainable service revenue and product commercialization.
Manageable Leverage And Tangible Equity BaseReported debt levels appear moderate for the sector, leaving room for continued R&D investment or capacity spending without immediate solvency pressure. Reasonable leverage provides financial flexibility to fund clinical programs or CDMO capacity over the medium term.
Bears Say
Revenue And Profit DeteriorationA large YoY revenue drop and reversion to losses signals weakening commercial traction or product/mix disruption. Over 2–6 months this undermines margin sustainability, reduces internal funding for R&D and commercialization, and raises execution risk for restoring prior growth trajectories.
Persistently Negative Free Cash FlowOngoing negative FCF forces reliance on external financing or equity issuance to fund operations and capex. For a biotech with R&D and manufacturing needs, this constrains strategic optionality, increases financing risk, and can pressure long-term investment in pipelines or manufacturing scale-ups.
Profitability And Margin VolatilityVolatile profits and recent gross-margin compression point to pricing, mix, or cost pressures that materially affect sustainable margins. This unpredictability complicates forecasting, limits return stability for shareholders, and may force tougher cost or pricing actions that harm long-term growth.
TOT BIOPHARM International Co. Ltd. News
1875 FAQ
What was TOT BIOPHARM International Co. Ltd.’s price range in the past 12 months?
TOT BIOPHARM International Co. Ltd. lowest stock price was HK$1.70 and its highest was HK$5.87 in the past 12 months.
What is TOT BIOPHARM International Co. Ltd.’s market cap?
TOT BIOPHARM International Co. Ltd.’s market cap is HK$3.38B.
When is TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date?
TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date is Aug 18, 2026 which is in 89 days.
How were TOT BIOPHARM International Co. Ltd.’s earnings last quarter?
TOT BIOPHARM International Co. Ltd. released its earnings results on Mar 18, 2026. The company reported -HK$0.158 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.158.
Is TOT BIOPHARM International Co. Ltd. overvalued?
According to Wall Street analysts TOT BIOPHARM International Co. Ltd.’s price is currently Overvalued.
Does TOT BIOPHARM International Co. Ltd. pay dividends?
TOT BIOPHARM International Co. Ltd. does not currently pay dividends.
What is TOT BIOPHARM International Co. Ltd.’s EPS estimate?
TOT BIOPHARM International Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TOT BIOPHARM International Co. Ltd. have?
TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding.
What happened to TOT BIOPHARM International Co. Ltd.’s price movement after its last earnings report?
TOT BIOPHARM International Co. Ltd. reported an EPS of -HK$0.158 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.695%.
Which hedge fund is a major shareholder of TOT BIOPHARM International Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1875
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TOT BIOPHARM International Co. Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.06%
12-Months-Change
Fundamentals
Return on Equity
-14.53%
Trailing 12-Months
Asset Growth
-12.65%
Trailing 12-Months
Company Description
TOT BIOPHARM International Co. Ltd.
BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.
Technical Analysis
Mabpharm Limited
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
Zhaoke Ophthalmology Ltd.
―
Immunotech Biopharm Ltd
―
Hightide Therapeutics Inc
―